Quantcast
Last updated on April 18, 2014 at 7:49 EDT

Latest Dimebolin Stories

2010-05-10 15:01:00

SAN FRANCISCO, May 10 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today provided a corporate update and reported its financial results for the first quarter ended March 31, 2010. "After thorough review of all available dimebon data, including the disappointing CONNECTION results, Medivation remains committed to determining whether dimebon may offer clinical benefit to Alzheimer's and Huntington disease patients," said David Hung, MD, president and chief executive officer of...

2010-05-03 07:00:00

SAN FRANCISCO, May 3 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss first quarter 2010 financial results and provide a general business update on May 10, 2010, at 4:30 p.m. Eastern Time. A press release for the first quarter ended March 31, 2010 will be released after markets close on May 10, 2010. Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally....

2010-03-29 15:01:00

SAN FRANCISCO, March 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that the Company is implementing a plan to reduce its workforce and operating costs in order to focus its resources on prioritized dimebon trials and the continued development of MDV3100. The Company will reduce the number of staff by 23, or approximately 20 percent. The reduction is effective March 29, 2010. "We need to take this difficult, yet necessary, step to manage our portfolio,...

2010-03-15 15:05:00

SAN FRANCISCO, March 15 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today provided a corporate update and reported its financial results for the year ended December 31, 2009. "We are disappointed by the results of the Phase 3 CONNECTION trial in Alzheimer's patients, and it is our highest priority to work with our colleagues at Pfizer to further analyze the data and determine next steps," said David Hung, M.D., president and chief executive officer of Medivation. "Despite...

2010-03-12 07:00:00

SAN FRANCISCO, March 12 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss fourth quarter and year-end 2009 financial results and provide a general business update on March 15, 2010, at 4:30 p.m. Eastern Time. A press release for the fourth quarter and year ended on December 31, 2009 will be released after markets close on March 15, 2010. Interested parties may call 877-303-2523 from the U.S....

2010-03-03 14:32:00

GENEVA, SWITZERLAND, March 3 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today issued a statement following today's announcement from Pfizer and Medivation (NASDAQ:MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials. "While this is disappointing for the Alzheimer's community, there have been many doubts expressed about Dimebon. These...

2010-03-02 19:25:00

SAN FRANCISCO, March 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time tomorrow, Wednesday, March 3, to discuss Phase 3 trial results for dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's Disease. A press release will be issued at 7:30 a.m. Eastern Time tomorrow prior to this call. Teleconference/Webcast Details To participate in the live call on Wednesday, March 3, at...

2010-03-01 07:00:00

SAN FRANCISCO, March 1 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences: The Cowen Healthcare Conference, Monday, March 8, at 4:45 p.m. Eastern Time at the Marriott Copley Place Hotel in Boston The ROTH 22nd Annual OC Growth Stock Conference, on Tuesday, March 16, at 12:30 p.m. Pacific Time at the Ritz-Carlton in Dana Point, Calif. Dr. Hung will provide...

2010-02-17 07:00:00

WALTHAM, Mass., Feb. 17, /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe Alzheimer's disease, a combination therapy that delays nursing home admission at 19 months would earn 43 percent patient share, according to surveyed U.S. neurologists. In comparison, in Europe, such an agent would earn a slightly lower patient share of 30 percent, according to...

2010-02-09 07:22:16

An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington's disease appears to be safe and may improve cognition. That is the conclusion of a study published Feb. 8 in the Archives of Neurology. "This is the first clinical trial that has focused on what is perhaps the most disabling aspect of the disease," said University of Rochester Medical Center neurologist Karl Kieburtz, M.D., the lead author of the study. "While more investigation needs to...